Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| PeposertibNCT04071236 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Other - To assess the study's feasibility. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| AvelumabNCT04071236 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Other - To assess the study's feasibility. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| SirolimusNCT06876142 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Administrative hold pending non-safety related changes to the study design. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| MirdametinibNCT06876142 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Administrative hold pending non-safety related changes to the study design. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| N-803NCT05642195 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Revisions to eligibility/design being made prior to enrollment of first participants. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| H1299 Cell LysatesNCT05642195 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Revisions to eligibility/design being made prior to enrollment of first participants. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| Montanide (Registered Trademark) ISA-51 VG AdjuvantNCT05642195 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Revisions to eligibility/design being made prior to enrollment of first participants. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| ChemotherapyNCT04638751 | Persephone BiosciencesPhase unknown | SUSPENDED Currently no funding to continue study. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| ImmunotherapyNCT04638751 | Persephone BiosciencesPhase unknown | SUSPENDED Currently no funding to continue study. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| VismodegibNCT06616623 | Dwight OwenPHASE1 | SUSPENDED Pending ICF update | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| AtezolizumabNCT06616623 | Dwight OwenPHASE1 | SUSPENDED Pending ICF update | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| BevacizumabNCT06039202 | Holy Stone Healthcare Co., LtdPHASE2 | SUSPENDED Strategy under discussion | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| TAS-102NCT06039202 | Holy Stone Healthcare Co., LtdPHASE2 | SUSPENDED Strategy under discussion | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| CA102NNCT06039202 | Holy Stone Healthcare Co., LtdPHASE2 | SUSPENDED Strategy under discussion | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| pemetrexedNCT06694454 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| gemcitabineNCT06694454 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| cisplatinNCT06694454 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| durvalumabNCT06694454 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| paclitaxelNCT06694454 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| carboplatinNCT06694454 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| azacytidineNCT06694454 | National Cancer Institute (NCI)PHASE1, PHASE2 | SUSPENDED Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| DexmedetomidineNCT04730609 | Mayo ClinicPHASE4 | WITHDRAWN Unable to start study. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| Ascorbic acidNCT04756063 | University of Wisconsin, MadisonPHASE4 | WITHDRAWN Staffing patterns | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| Curcumin-phosphatidylcholineNCT04800107 | Henry Ford Health SystemNA | WITHDRAWN Study was not pursued after joint venture completed with Henry Ford Health. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-18 |
| KetamineNCT03362073 | Pusan National University Yangsan HospitalPHASE2 | TERMINATED The study was terminated early due to the principal investigator's transition to another institution. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-18 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |
Page 1 · Next